Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Expert Rev Clin Pharmacol. 2011 May;4(3):363–377. doi: 10.1586/ecp.11.18

Figure 2. The summary effect size and 95% confidence intervals for the association between concurrent use of (A) a weak CYP2D6 inhibitor drug and (B) a strong CYP2D6 inhibitor drug and breast cancer recurrence/survival.

Figure 2

Summary ES and 95% confidence intervals were estimated using a fixed-effects meta-analytical model. All statistical tests were two-sided. The size of each square is an illustrative representation of the study weight. The horizontal lines represent the CIs. The diamond represents the summary ES and 95% CIs.

CI: Confidence interval; ES: Effect size.